Heparin and protamine interaction.
G
G
Blaise
D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects*; D006493:Heparin / Q000009:adverse effects*; D006494:Heparin Antagonists / Q000009:adverse effects*; D006976:Hypertension, Pulmonary / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced / Q000517:prevention & control; D008168:Lung / Q000098:blood supply; D009200:Myocardial Contraction / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000139:chemically induced / Q000517:prevention & control; D019331:NG-Nitroarginine Methyl Ester / Q000627:therapeutic use; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011479:Protamines / Q000009:adverse effects*; D051381:Rats; D015427:Reperfusion Injury / Q000139:chemically induced / Q000517:prevention & control
D000925:Anticoagulants; D004791:Enzyme Inhibitors; D006494:Heparin Antagonists; D011479:Protamines; D006493:Heparin; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester